Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study.
Pentosan polysulfate sodium (PPS) was compared with placebo for the symptomatic therapy of interstitial cystitis in a double-blind, multicenter study. A total of 110 patients were enrolled and treated for three months. In this study, overall improvement of greater than 25 percent was reported by 28 percent of the PPS-treated patients and by 13 percent of the placebo-treated patients (p = 0.03). The investigators' overall evaluation provided similar results, 26 percent vs 11 percent in favor of PPS (p = 0.04). Improvement in pain and pressure to urinate also favored PPS over placebo and approached statistical significance (p = 0.07 and 0.08). The incidence of adverse reactions was 6 percent in the PPS-treated group and 13 percent in the placebo-treated group. All adverse reactions were minor, and treatment was discontinued by 1 patient in the PPS group and 2 in the placebo group. In this study, PPS was found to be significantly more effective than, and equally as safe as, placebo.
Department of Urology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
S G
SG
Mulholland
P
P
Hanno
C L
CL
Parsons
G R
GR
Sant
D R
DR
Staskin
D000328:Adult; D003556:Cystitis / Q000188:drug therapy* / Q000652:urine; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D010147:Pain Measurement / Q000187:drug effects; D010426:Pentosan Sulfuric Polyester / Q000009:adverse effects / Q000627:therapeutic use*; D011134:Polysaccharides / Q000627:therapeutic use*
D011134:Polysaccharides; D010426:Pentosan Sulfuric Polyester